Gold(I)-triphenylphosphine complexes with hypoxanthine-derived ligands: In vitro evaluations of anticancer and anti-inflammatory activities

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Křikavová, Radka ^a   Hošek, Jan ^a   Vančo, Ján ^a   Hutyra, Jakub ^a   Dvořák, Zdeněk ^a   Trávníček, Zdeněk ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; AURANOFIN; CISPLATIN; CYSTEINE; CYTOKINE; GLUTATHIONE; GOLD COMPLEX; HYPOXANTHINE; INTERLEUKIN 1BETA; LIGAND; LIPOPOLYSACCHARIDE; SULFUR; TRIPHENYLPHOSPHINE; TUMOR NECROSIS FACTOR ALPHA; GOLD; ORGANOPHOSPHORUS COMPOUND;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LUNG ADENOCARCINOMA; MASS SPECTROMETRY; MELANOMA; MONOCYTIC LEUKEMIA; OSTEOSARCOMA; OVARY CARCINOMA; PROSTATE CANCER; UTERINE CERVIX CANCER; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; MACROPHAGE; METABOLISM; NUCLEAR MAGNETIC RESONANCE; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; GOLD; HUMANS; HYPOXANTHINE; MACROPHAGES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; ORGANOPHOSPHORUS COMPOUNDS;

EID: 84907167228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107373     Document Type: Article

References (50)

1. Berners-Price SJ (2011) Gold-Based Therapeutic Agents: A New Perspective. In: Bioinorganic Medicinal Chemistry. Alessio E, (Ed.). Weinheim: Wiley-VCH, Germany, 197-222.
2. Ho SI, Tiekink ERT (2005) Gold-Based Metallotherapeutics: Use and Potential. In: Metallotherapeutic Drugs and Metal-based Diagnostic Agents: The Use of Metals in Medicine. Gielen M, Tiekink ERT (Eds.). London: John Wiley and Sons, Ltd., England.
3. Shaw III CF (1999) Gold-Based Therapeutic Agents. Chem Rev 99: 2589-2600.
4. Berners-Price SJ, Filipovska A (2011) Gold compounds as therapeutic agents for human diseases. Metallomics 3: 863-873.
5. Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, et al. (1974) Gold Salts in the Treatment of Rheumatoid Arthritis: A Double-Blind Study. Ann Intern Med 80: 21226.
6. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, et al. (1992) Comparison of Auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 35: 2592269.
7. Kean WF, Hart L, Buchanan WW (1997) Auranofin. Br J Rheumatol 36: 560-572.
8. Madeira JM, Gibson DL, Kean WF, Klegeris A (2012) The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacol 20: 297-306.
9. Rau R (2005) Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents. Clin Rheumatol 24: 189-202.
10. Ott I (2009) On the medicinal chemistry of gold complexes as anticancer drugs. Coord Chem Rev 253: 1670-1681.
11. Barreiro E, Casas JS, Couce MD, Sanchez-Gonzalez A, Sordo J, et al. (2008) Synthesis, structure and cytotoxicity of triphenylphosphinegold(I) sulfanylpropenoates. J Inorg Biochem 102: 184-192.
12. Ott I, Qian X, Xu Y, Kubutat D, Will J, et al (2009) A gold(I) phosphine complex containing naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J Med Chem 52, 763-770.
13. Gallassi R, Burini A, Ricci S, Pellei M, Rigobello MP, et al. (2012) Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents. Dalton Trans 41: 5307-5318.
14. Abbehausen C, Peterson EJ, de Paiva RE, Corbi PP, Formiqa AL, et al. (2013) Gold(I)-phosphine-N-heterocycles: biological activity and specific (ligand) interactions on the C-terminal HIVNCp7 zinc finger. Inorg Chem 52: 11280-11287.
15. Trávníček Z, Štarha P, Vančo J, Šilha T, Hošek J, et al. (2012) Antiinflammatory Active Gold(I) Complexes Involving 6-substituted Purine Derivatives. J Med Chem 55: 4568-4579.
16. Hošek J, Vančo J, Štarha P, Paráková L, Trávníček Z (2013) Effect of 2-Chloro-Substitution of Adenine Moiety in Mixed-Ligand Gold(I) Triphenylphosphine Complexes on Anti-Inflammatory Activity: The Discrepancy between the In Vivo and In Vitro Models. PLoS ONE 8(11): e82441.
17. Craig S, Gao L, Lee I, Gray T, Berdis AJ (2012) Gold-Containing Indoles as Anticancer Agents That Potentiate the Cytotoxic Effects of Ionizing Radiation. J Med Chem 55: 2437-2451.
18. Gandin V, Fernandes AP, Rigobello MP, Dani B, Sorrentino F, et al. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem Pharmacol 79: 90-101.
19. Gibson AE, Arris CE, Bentley J, Boyle FT, Curtin NJ, et al. (2002) Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 with O6-Substituted Guanine Derivatives. J Med Chem 45: 3381-3393.
20. Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, et al. (2000) Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles. J Med Chem 43: 2797-2804.
21. Griffin RJ, Arris CE, Bleasdale C, Boyle FT, Calvert AH, et al. (2000) Resistance-Modifying Agents. 8. Inhibition of O6-Alkylguanine-DNA Alkyltransferase by O6-Alkenyl-, O6-Cycloalkenyl-, and O6-(2-Oxoalkyl)guanines and Potentiation of Temozolomide Cytotoxicity in Vitro by O6-(1-Cyclopentenylmethyl) guanine. J Med Chem 43: 4071-4083.
22. 6-Substituted Guanine Derivatives and their Application in Medicine. Curr Org Synth 2: 215-230.
23. Štarha J, Hošek J, Vančo J, Dvořák Z, Suchý Jr P, et al. (2014) Pharmacological and Molecular Effects of Platinum(II) Complexes Involving 7-Azaindole Derivatives. PLoS ONE 9: e90341.
24. Vrzal R, Štarha P, Dvořák Z, Trávníček Z (2010) Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands. J Inorg Biochem 104: 1130-1132.
25. Buchtík R, Trávníček Z, Vančo J (2012) In vitro cytotoxicity, DNA cleavage and SOD-mimic activity of copper(II) mixed-ligand quinolinonato complexes. J Inorg Biochem 116: 163-171.
26. Trávníček Z, Vančo J, Hošek J, Buchtík R, Dvořák Z (2012) Cellular responses induced by Cu(II) quinolinonato complexes in human tumor and hepatic cells. Chem Centr J 6: 160.
27. Trávníček Z, Matiková-Ma̘arová M, Novotná R, Vančo J, Štěpánková K, et al. (2011) In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A. J Inorg Biochem 105: 937-948.
28. Křikavová R, Hošek J, Suchý P, Vančo J, Trávníček Z (2014) Diverse in vitro and in vivo anti-inflammatory effects of trichlorido-gold(III) complexes with N6-benzyladenine derivatives. J Inorg Biochem 134: 92-99.
29. Vančo J, Marek J, Trávníček Z, Račanská E, Muselík J, et al. (2008) Synthesis, structural characterization, antiradical and antidiabetic activities of copper(II) and zinc(II) Schiff base complexes derived from salicylaldehyde and betaalanine. J Inorg Biochem 102: 595-605.
30. Mann FG, Wells AF, Purdie D (1937) The constitution of complex metallic salts. Part VI. The constitution of the phosphine and arsine derivatives of silver and aurous halides. The configuration of the coordinated argentous and aurous complex. J Chem Soc: 1828-1836.
31. Bruce MI, Nicholson BK, Shawkataly bin O, Shapley JR, Henly T (1989) Synthesis of gold-containing mixed-metal cluster complexes. Inorg Syn 26: 324-328.
32. Oxford Diffraction, CrysAlis RED and CrysAlis CCD Software (Ver. 1.171.33.52), Oxford Diffraction Ltd., Abingdon, Oxfordshire, UK.
33. Sheldrick GM (2008) Short History of SHELX. Acta Crystallogr, Sect A 64: 112-122.
34. Brandenburg K (2011) DIAMOND, Release 3.2i, Crystal Impact GbR, Bonn, Germany.
35. Macrae CF, Bruno IJ, Chisholm JA, Edgington PR, McCabe P, et al. (2008) Mercury CSD 2.0 - new features for the visualization and investigation of crystal structures. J Appl Cryst 41: 466-470.
36. Salemi G, Gueli MC, D'Amelio M, Saia V, Mangiapane P, et al. (2009) Blood levels of homocysteine, cysteine, glutathione, folic acid, and vitamin B12 in the acute phase of atherothrombotic stroke. Neurol Sci 30: 361-364.
37. Nakamoto K (1997) Infrared Spectra of Inorganic and Coordination Compounds, Part B, Applications in Coordination, Organometallic, and Bioinorganic Chemistry. Wiley, New York, USA.
38. Smith BC (1999) Infrared Spectral Interpretation: A Systematic Approach. CRC Press LLC, Florida, USA.
39. Faggianhi R, Howard-Locck HE, Lock CJL, Turner MA (1987) The reaction of chloro(triphenylphosphine)gold(I) with 1-methylthymine. Can J Chem 65: 1568-1575.
40. Allen FH (2002) The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr Sect B Struct Sci 58: 380-388.
41. Kouroulis KN, Hadjikakou SK, Kourkoumelis N, Kubicki M, Male L, et al. (2009) Synthesis, structural characterization and in vitro cytotoxicity of new Au(III) and Au(I) complexes with thioamides. Dalton Trans 47: 10446-10456.
42. Ott I, Schmidt K, Kircher B, Schumacher P, Wiglenda T, et al. (2005) Antitumor-Active Cobalt-Alkyne Complexes Derived from Acetylsalicylic Acid: Studies on the Mode of Drug Action. J Med Chem: 48 622-629.
43. Seitz M, Valbracht J, Quach J, Lotz M (2003) Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 23: 477-484.
44. Han S, Kim K, Kim H, Kwon J, Lee YH, et al. (2008) Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE(2) production in macrophages. Arch Pharmacal Res 31: 67-74.
45. Hayden MS, Ghosh S (2008) Shared principles in NF-kappa B signaling. Cell 132: 344-362.
46. Jeon KI, Jeong JY, Jue DM (2000) Thiol-reactive metal compounds inhibit NFkappa B activation by blocking I kappa B kinase. J Immunol 164: 5981-5989.
47. Shaw CF, Coffer MT, Klingbeil J, Mirabelli CK (1988) Application of phosphorus-31 NMR chemical shift: gold affinity correlation to hemoglobin-gold binding and the first inter-protein gold transfer reaction. J Am Chem Soc 110: 729-734.
48. Iqbal MS, Taqi SG, Arif M, Wasim M, Sher M (2009) In vitro distribution of gold in serum proteins after incubation of sodium aurothiomalate and auranofin with human blood and its pharmacological significance. Biol Trace Elem Res 130: 204-209.
49. Saccoccia F, Angelucci F, Boumis G, Brunori M, Miele AE, et al. (2012) On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases. J Inorg Biochem 108: 105-111.
50. Lewis D, Capell HA, McNeil CJ, Iqbal MS, Brown DH, et al. (1983) Gold levels produced by treatment with auranofin and sodium aurothiomalate. Ann Rheum Dis 42: 566-570.